NCT04579380: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must progressed on or after more than 1 prior line of treatment (e.g., chemotherapy, endocrine therapy, or targeted therapy); Patients with metastatic HR+ HER2-mutated disease must have received a prior CDK4/6 inhibitor in the metastatic setting
Exclusions: Patients with HER2 overexpression/amplification (HER2+); Patients with previous treatment of HER2-directed therapy; Patients with history of exposure to a 360 mg/m² doxorubicin-equivalent or more than 720 mg/m² epirubicin-equivalent cumulative dose of anthracyclines

Comments are closed.

Up ↑